Cost-effectiveness analysis of influenza vaccination with high-dose vaccine versus standard-dose quadrivalent vaccine in older adults in Spain.

IF 3.1 3区 医学 Q1 ECONOMICS
European Journal of Health Economics Pub Date : 2026-09-01 Epub Date: 2026-03-04 DOI:10.1007/s10198-026-01894-8
Jose-Maria Abellan-Perpiñan, Esther Redondo Margüello, Ángel Gil de Miguel, Iván Sanz Muñoz, Ariadna Diaz-Aguiló, Paloma Palomo, Manel Farré, Daniel Callejo, Marco Pinel, Juan Luis López-Belmonte
{"title":"Cost-effectiveness analysis of influenza vaccination with high-dose vaccine versus standard-dose quadrivalent vaccine in older adults in Spain.","authors":"Jose-Maria Abellan-Perpiñan, Esther Redondo Margüello, Ángel Gil de Miguel, Iván Sanz Muñoz, Ariadna Diaz-Aguiló, Paloma Palomo, Manel Farré, Daniel Callejo, Marco Pinel, Juan Luis López-Belmonte","doi":"10.1007/s10198-026-01894-8","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction and objectives: </strong>Influenza is a widespread acute respiratory illness which represents a significant public health challenge from both the National Health Service (NHS) and societal perspective, especially in the older adults. The aim of this study was to assess the cost-effectiveness of influenza vaccination with a high-dose quadrivalent vaccine (HD-QIV) versus a standard dose quadrivalent vaccine (SD-QIV) in the older adults in Spain.</p><p><strong>Methods: </strong>We assessed the public health and economic benefits of various alternatives using a decision-tree model. This model considered factors such as influenza cases, visits to general practitioners (GP), emergency department (ED) visits, hospitalizations due to cardiorespiratory events, and influenza-related mortality. To address uncertainties deriving from both epidemiological and economic sources, we conducted deterministic and probabilistic sensitivity analyses.</p><p><strong>Results: </strong>From a societal perspective, HD-QIV compared to SD-QIV prevented during an influenza season 54,039 influenza cases, 7,733 GP consultations, 1,585 ED visits, 30,772 episodes of hospitalization due to cardiorespiratory events over a single influenza season and 1,203 deaths when vaccinating adults ≥ 65 years old in Spain, resulting in 14,316 LYs and 12,545 QALYs gained over a lifetime horizon. The reduction in health outcomes outweighed the increase in vaccination costs, translating to a reduction in total costs with HD-QIV compared to SD-QIV. Therefore, vaccinating older adults in Spain with HD-QIV instead of SD-QIV was a dominant strategy when evaluating hospitalizations due to cardiorespiratory events. HD-QIV remained dominant from an NHS perspective. Sensitivity analyses confirmed the robustness of the model.</p><p><strong>Conclusions: </strong>This analysis showed that vaccinating older adults in Spain with HD-QIV instead of SD-QIV would reduce cases of influenza, GP and ED visits, hospitalizations, deaths, and associated costs, and thus it should be the strategy of choice in a situation of budgetary constraints from either a societal or an NHS perspective.</p>","PeriodicalId":51416,"journal":{"name":"European Journal of Health Economics","volume":" ","pages":"1497-1508"},"PeriodicalIF":3.1000,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13619801/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Health Economics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10198-026-01894-8","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/3/4 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"ECONOMICS","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction and objectives: Influenza is a widespread acute respiratory illness which represents a significant public health challenge from both the National Health Service (NHS) and societal perspective, especially in the older adults. The aim of this study was to assess the cost-effectiveness of influenza vaccination with a high-dose quadrivalent vaccine (HD-QIV) versus a standard dose quadrivalent vaccine (SD-QIV) in the older adults in Spain.

Methods: We assessed the public health and economic benefits of various alternatives using a decision-tree model. This model considered factors such as influenza cases, visits to general practitioners (GP), emergency department (ED) visits, hospitalizations due to cardiorespiratory events, and influenza-related mortality. To address uncertainties deriving from both epidemiological and economic sources, we conducted deterministic and probabilistic sensitivity analyses.

Results: From a societal perspective, HD-QIV compared to SD-QIV prevented during an influenza season 54,039 influenza cases, 7,733 GP consultations, 1,585 ED visits, 30,772 episodes of hospitalization due to cardiorespiratory events over a single influenza season and 1,203 deaths when vaccinating adults ≥ 65 years old in Spain, resulting in 14,316 LYs and 12,545 QALYs gained over a lifetime horizon. The reduction in health outcomes outweighed the increase in vaccination costs, translating to a reduction in total costs with HD-QIV compared to SD-QIV. Therefore, vaccinating older adults in Spain with HD-QIV instead of SD-QIV was a dominant strategy when evaluating hospitalizations due to cardiorespiratory events. HD-QIV remained dominant from an NHS perspective. Sensitivity analyses confirmed the robustness of the model.

Conclusions: This analysis showed that vaccinating older adults in Spain with HD-QIV instead of SD-QIV would reduce cases of influenza, GP and ED visits, hospitalizations, deaths, and associated costs, and thus it should be the strategy of choice in a situation of budgetary constraints from either a societal or an NHS perspective.

西班牙老年人接种高剂量流感疫苗与标准剂量四价流感疫苗的成本-效果分析
简介和目标:流感是一种广泛存在的急性呼吸道疾病,从国家卫生服务(NHS)和社会的角度来看,它都是一个重大的公共卫生挑战,特别是在老年人中。本研究的目的是评估西班牙老年人使用高剂量四价疫苗(HD-QIV)与标准剂量四价疫苗(SD-QIV)接种流感疫苗的成本效益。方法:我们使用决策树模型评估了各种替代方案的公共卫生和经济效益。该模型考虑了流感病例、全科医生(GP)就诊、急诊科(ED)就诊、因心肺事件住院以及流感相关死亡率等因素。为了解决来自流行病学和经济来源的不确定性,我们进行了确定性和概率敏感性分析。结果:从社会角度来看,与SD-QIV相比,HD-QIV在流感季节预防了54,039例流感病例,7,733例全科医生咨询,1,585例急诊就诊,30,772例因单一流感季节心血管事件住院,1,203例死亡,接种疫苗的西班牙65岁以上成年人,在一生中获得了14,316个LYs和12,545个QALYs。健康结果的减少超过了疫苗接种成本的增加,与SD-QIV相比,HD-QIV转化为总成本的降低。因此,在评估因心肺事件而住院的情况时,西班牙老年人接种HD-QIV而不是SD-QIV是一种主要策略。从NHS的角度来看,HD-QIV仍然占主导地位。敏感性分析证实了模型的稳健性。结论:该分析表明,在西班牙为老年人接种HD-QIV而不是SD-QIV可以减少流感病例、GP和ED就诊、住院、死亡和相关费用,因此,从社会或NHS的角度来看,在预算限制的情况下,这应该是一种选择策略。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
6.10
自引率
2.30%
发文量
131
期刊介绍: The European Journal of Health Economics is a journal of Health Economics and associated disciplines. The growing demand for health economics and the introduction of new guidelines in various European countries were the motivation to generate a highly scientific and at the same time practice oriented journal considering the requirements of various health care systems in Europe. The international scientific board of opinion leaders guarantees high-quality, peer-reviewed publications as well as articles for pragmatic approaches in the field of health economics. We intend to cover all aspects of health economics: • Basics of health economic approaches and methods • Pharmacoeconomics • Health Care Systems • Pricing and Reimbursement Systems • Quality-of-Life-Studies The editors reserve the right to reject manuscripts that do not comply with the above-mentioned requirements. The author will be held responsible for false statements or for failure to fulfill the above-mentioned requirements. Officially cited as: Eur J Health Econ
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书